Get the Stockscreener App
27.39
4.26%
-1.22
After Hours:
27.35
-0.04
-0.15%
Hims Hers Health Inc stock is traded at $27.39, with a volume of 7.88M.
It is down -4.26% in the last 24 hours and down -16.60% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$28.61
Open:
$27.85
24h Volume:
7.88M
Relative Volume:
0.48
Market Cap:
$6.39B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
52.46
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-10.23%
1M Performance:
-16.60%
6M Performance:
+72.92%
1Y Performance:
-39.27%
1-Day Range:
$27.38
$28.85
1-Week Range:
$27.38
$30.99
52-Week Range:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.39 | 6.68B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.05 | 55.50B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.72 | 42.14B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.58 | 42.49B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.96 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
518.27 | 21.81B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following - GlobeNewswire
Hims & Hers CEO Andrew Dudum Says AI Health Coach Could Be Just 12 Months Away, Believes It Could Increase Medication Adherence - Stocktwits
Kaplan Fox Announces an Investigation Into Hims & Hers Health, In - The National Law Review
Hims & Hers Health Options Spot-On: On August 18th, 65,547 Contracts Were Traded, With 886.89K Open Interest - Moomoo
HIMS Looks 34.0% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Hims CEO sees GLP-1 prices falling to $40$50 (HIMS:NYSE) - Seeking Alpha
Hims & Hers CEO Andrew Dudum pushes back on FTC lawsuit - qz.com
Hims & Hers CEO pushes back against FTC suit, says "we are active disruptors" - Investing.com Nigeria
Hims & Hers CEO Tells the FTC That Regulators Just Don’t Understand - Yahoo Finance
Hims & Hers CEO says FTC lawsuit misunderstands how the company works - CNBC
Hims & Hers: Eucalyptus Deal Unlocks New Markets (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health Stock Short Interest Rises to 32.05% - Quiver Quantitative
HIMS Stock Has Quadrupled In 5 Years: How Hims Turned A $3 Stock Into A Telehealth Giant - Stocktwits
Hims & Hers Stock (HIMS) Opinions on Five-Year Public Listing Anniversary - Quiver Quantitative
Financial Markets Wall Street - Dayton Daily News
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to Possible Securities Law Violations - The National Law Review
HIMS Stock Snaps 2-Day Climb: Analyst Says Record Subscriber Growth ‘Not Enough’ To Offset Margin Slide - Stocktwits
5 Revealing Analyst Questions From Hims & Hers Health’s Q2 Earnings Call - Yahoo Finance
HIMS Stock Climbs Overnight: Oscar Health CEO Courts Hims For New Drug Marketplace - Stocktwits
Citi Says Hims & Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks - Stocktwits
Hims & Hers Health (NYSE:HIMS) Upgraded to Hold at Wall Street Zen - MarketBeat
Hims & Hers Health, Inc. • Robinhood Token Price, HIMS Price, Live Charts, and Marketcap - Coinbase
Hims & Hers Health CTO Mohamed Elshenawy Awarded 1.2 Million RSUs - Kalkine Media
Hims & Hers Health Director Christopher D. Payne Awarded 8,768 RSUs in August 2026 - Kalkine Media
Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset? - Yahoo Finance
Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop - pluang.com
Hims & Hers Health's Next Act: Making Its Own Drugs Again (NYSE:HIMS) - Seeking Alpha
Investor relations - HIMS investor relations
Kaplan Fox Reminds Investors of Hims & Hers Health, Inc. (NYSE: H - The National Law Review
Hims & Hers Health Inc (HIMS) Shares Fall 4.0% -- What GF Score of 78 Tells Investors - GuruFocus
Kaplan Fox is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Securities Law Violations - The National Law Review
HIMS Q2 Deep Dive: AI Strategy and International Expansion Shape Telehealth Outlook - Yahoo Finance
HIMS Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Utah sues Hims over alleged 'subscription trap,' sharing of private health data - St. George News
Securities Fraud Investigation Into Hims & Hers Health, - GlobeNewswire
FTC lawsuit alleges Hims & Hers charged consumers for unwanted prescriptions - Top Class Actions
HIMS SHAREHOLDER ALERT: Hims & Hers Health, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations - Business Wire
A Major Telehealth Company Will Sell Longevity Peptides That Clinical Evidence Has Not Yet Backed - Medical Daily
Hims & Hers upgrades women's health app with AI, smart scale integration - TechTarget
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Hims & Hers Health, Inc. (HIMS) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Hims & Hers shared patient health data with Meta, Snap and other advertisers, new class action lawsuit claims - Claim Depot
NYSE: HIMS Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm - Morningstar
As Hims prepares for peptides launch, Wall Street cautious on prospects this year - Reuters
Investigation launched into Hims & Hers for all... - Pluang
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS) - marketscreener.com
Hims & Hers’ Revenue Beat Came With a Profitability Problem - MarketBeat
Hims & Hers: The Guidance Raise Doesn't Fix The Margin Problem (NYSE:HIMS) - Seeking Alpha
Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) LawsuitInvestors Urged to Contact Levi & Korsinsky Before August 25, 2025 - The National Law Review
Hims & Hers Health: Algorithmic Transformation of Consumer Healthcare - healthcare.digital
Hims & Hers Q2 Revenue Jumps 38% as International Expansion Accelerates - globalcosmeticsnews.com
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):